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Abstract Amongst the chromogranin B (CGB) derived frag- 
ments naturally generated in bovine chromaffin granules and 
detected in the extracellular space, we recently identified a major 
peptide corresponding to the 614--626 sequence of CGB. This 
peptide, named secretolytin, shared an interesting sequence ho- 
mology with the lyric domain of cecropins and displayed a potent 
antibacterial activity. The aim of the present study was to deter- 
mine the structural features of secretolytin necessary for this 
biological activity. Our results suggest hat an a-helical amphipa- 
thic structure common to secretolytin, cecropins and pig myeloid 
antibacterial peptide may account for the antibacterial activity. 
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1. Introduction 
Chromogranins are proteins tored in secretory granules of 
many endocrine cells, neuroendocrine c lls and neurons [1]. 
The widespread occurrence of chromogranins in mammals as 
well as in primitive living organisms uggests that important 
biological roles remain to be defined. An intracellular function 
as a helper protein in the packaging of peptide hormones and 
neuropeptides and as modulators of the processing of these 
components has been suggested [2]. Within chromaffin gran- 
ules, chromogranin A, B and C (CGA, CGB/SgI, CGC/SglI) 
represent more than 80% of the soluble proteins [3,4] and they 
are actively processed [5-7]. Because of the occurrence of nu- 
merous chromogranin-derived p ptides, an extracellular role as 
a precursor to biologically active peptides has also been pro- 
posed [1]. 
A major short 13-residue peptide corresponding to the 614- 
626 C-terminal region of CGB has recently been identified 
amongst he CGB-fragments naturally released into the ex- 
tracellular medium from depolarized bovine cultured chro- 
maffin cells [7]. In this study, we reported a strong relationship 
between the sequence of secretolytin and the N-terminal lyric 
helix of cecropins. Cecropins are a family of strongly basic 
*Corresponding author. Fax: (33) (88) 60-08-06. 
Abbreviations: CGA, chromogranin A; CGB, chromogranin B/secreto- 
granin I; CGC, chromogranin C/secretogranin II; PMAP-37, pig my- 
eloid antibacterial peptide. 
Secretolytin sequence has been deposited in the EMBL sequence data 
bank and is available under accession umber P23389. 
peptides with very potent antibacterial ctivity, that were first 
isolated from the hemolymph of Drosophila [8], then from the 
giant silk moth, Hyalophora cecropia [9,10], and subsequently 
from a wide range of other insects [11]. Later, an antibacterial 
peptide with 33% homology to insect cecropins was isolated 
from porcine small intestine [12]. More recently, a new anti- 
bacterial peptide was isolated from pig myeloid cells (PMAP- 
37): its sequence also shows a high degree of similarity with the 
N-terminal helix of cecropin domain [13]. The isolation of ce- 
cropin from mammalian sources and from cuticular matrix [14] 
suggests that cecropins are widely distributed in the animal 
kingdom and are active mediators of innate immunity [15]. 
Recent efforts have been directed towards understanding the 
mechanism of action of the cecropins and their derivatives. 
Studies using chemically synthesized selective analogues have 
established that the active peptides do not function by chiral 
interactions with either receptors, enzymes or lipids. However, 
the mechanism leading to the death of a bacterium is not yet 
understood. 
The aim of the present study was to identify the structural 
features of secretolytin that are necessary for its antibacterial 
activity. Synthetic related peptides were prepared taking into 
consideration modifications related to the length of secretolytin 
and the distribution of polar and hydrophobic residues. Com- 
puter design models of secretolytin and derived peptides were 
constructed and are discussed in relation to their antibacterial 
activity. 
2. Materials and methods 
2.1. Materials 
Chemicals (analytical grade) were from Sigma or Prolabo except 
those mployed for the protein microsequencer and the peptide synthe- 
sizer which were obtained from Applied Biosystems (Perkin Elmer). 
Micrococcus luteus (strain A 270) and Bacillus megaterium (strain M A) 
were purchased from the Pasteur Institute. 
2.2. Peptide synthesis 
Peptides were synthesized in our laboratory on an Applied Biosys- 
tems 432 A peptide synthesizer, SYNERGY, using the stepwise solid- 
phase synthetic approach and 9-fluorenylmethoxycarbonyl (Fmoc) 
chemistry [16]. All residues were incorporated with a double coupling. 
Peptides were further purified by reverse-phase HPLC on a Brownlee 
Aquapore OD-300 (7 mm x 250 mm) and lyophilized. 
2.3. Sequence analysis 
The N-terminal sequence of purified synthetic peptides was deter- 
mined by automatic Edman degradation an Applied Biosystems 473 
A microsequencer, Samples purified by HPLC were loaded onto 
polybrene-treated an precycled glass-fibre filters [7]. Phenylthiohydan- 
toin amino acids were identified by chromatography on a PTH C-18 
column (2.1 mm x 200 mm). 
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2.4. Mass spectrometry 
Mass analyses were performed using electrospray mass spectrometry 
technique (ESMS) on a VG Bio-Q quadrupole with a mass range of 
4000 Da (Bio-Tech, Manchester, UK) in the positive mode [17]. The 
peptide (50 pmol) was dissolved in 10/21 of acetic acid/water/acetonitrile 
(1/49/50; v/v/v) and introduced into the ion source at a flow rate of 4 
/21/min. Scanning was usually performed from m/z -- 500 to m/z -- 1500 
in 10 s and the resolution was adjusted so that the peak at m/z = 998 
from horse heart myoglobin was 1.5-2 wide on the foot. Calibration 
was performed using the multiply-charged ions produced by a separate 
introduction of horse heart myoglobin (169550.4 Da). 
2.5. Antibacterial ctivity 
Bacteria were grown aerobically at 37°C in yeast extract-free Luria- 
Bertani medium (1% Bactotryptone, 0.5% NaC1 (m/v), pH 7.5). Anti- 
microbial activity was established from the growth inhibition of Micro- 
coccus luteus (strain A 270) and/or Bacillus megaterium (strain M A) 
(in Luria-Bertani medium) according to the method previously de- 
scribed [18]. Aliquots of peptide xtract (200 pmol; 10/21) were incu- 
bated in microtiter plates with 100/21 of a midlogarithmic phase culture 
of bacteria with a starting absorbance at 620 nm of 0.001. Microbial 
growth was assessed by the increase of A620 nm after 16 h incubation 
at 37°C (Micrococcus luteus) or 20°C (Bacillus megaterium). The A620 
nm value of control cultures growing in the absence of peptide (10/21 
of water in place of peptide solution) was taken as 100%. 
2.6. Sequence omparisons 
Sequence alignment of secretolytin (bovine CGB 614-626) with cor- 
responding fragments of human, rat and mouse CGB, of cecropins 
from different species and of PMAP-37 was performed using the Clustal 
V multiple sequence alignment program [19] using default parameters. 
Chromogranin, cecropin and PMAP-37 sequences were retrieved from 
the Swiss-Prot database. 
2. 7. Computer p edicted models 
The models of secretolytin, its related peptides and PMAP-37 were 
built taking into account he sequence similarity of secretolytin and 
cecropin (Antpe) from Antheraea Pernyi (chinese oak silk worm; pro- 
tein Data Bank entry P01509) and using the program Pro-Explore 
(Oxford molecular, Oxford, UK). 
3. Results and discussion 
The purpose of this work was to examine the relationship 
between the structure and the antibacterial activity of secre- 
tolytin, the 614-626 fragment of bovine CGB and to establish 
whether the amphipathic a-helix model previously proposed 
for cecropins [20,21] might also account for the interaction of 
secretolytin with bacterial membranes. 
3.1. Characterization of the residues necessary for the 
antibacterial ctivity of secretolytin 
In order to characterize the residues important for the anti- 
bacterial activity of secretolytin, this peptide (1) and several 
related peptides numbered 2 to 10, were synthesized (Fig. 1A). 
During storage of secretolytin, we observed the natural forma- 
tion of a pyrolidone glutamic acid at the N-terminal end, giving 
a molecular mass of 1460 Da. This peptide was isolated after 
HPLC purification (peptide 2). The synthetic peptide 3 (molec- 
ular mass of 1292 Da) has two deleted residues (G9, T10) and 
R11 changed into Q11 and corresponds to the C-terminal CGB 
peptide of several species (human, rat and mouse). Peptide 4 
(molecular mass of 1052 Da) corresponds to a shorter form of 
secretolytin. In peptides 5 and 6 (molecular mass 1421 Da), the 
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Fig. 1. Antibacterial ctivity of synthetic secretolytin-derived p ptides. 
(A), Amino acid sequence of the different synthetic peptides (peptide 
1-10) was characterized after complete automatic Edman degradation, 
and molecular mass was obtained using electrospray mass spectrometry 
technique (ESMS). Q*, corresponds to the natural formation of py- 
rolidone glutamic acid. The mixture of peptides resulting of the tryptic 
digest of secretolytin was numbered 11. (B), Peptides 1-11 were tested 
against Micrococcus luteus (strain A 270) by incubation with 2/2M of 
peptide in yeast-extract-free Luria-Bertani medium (100/21). The micro- 
bial growth was assessed by measuring the increase at 620 nm after 
incubation for 16 h at 37°C (grey columns la and 2-11). Peptide 1 
(secretolytin) was also tested against Bacillus megaterium (strain M A; 
white column lb). The microbial growth was assessed by measuring the 
increase at 620 nm after incubation for 16 h at 20°C. Values found with 
control cultures grown in the absence of peptide was taken as 0%. Data 
are typical of several experiments and are given +10%. 
two basic K residues in positions 6 and 2 were alternatively 
changed into A. In peptide 7 (molecular mass 1360 Da), two 
A residues were included instead of the two hydrophobic resi- 
dues I3 and F7. In addition, a mixture of peptides resulting 
from a tryptic digest of secretolytin was used as a control (line 
11, Fig. 1A). 
The antibacterial activity against Micrococcus luteus was 
measured for each peptide (1-10 in Fig. 1A). Secretolytin and 
its pyrolidone glutamic derivative displayed antibacterial ctiv- 
ity against Micrococcus luteus, reaching 100% activity around 
2~tM ( la and 2 in Fig. 1B). In addition, secretolytin was active 
in the micromolar concentration range towards another bacte- 
ria gram-positive, Bacillus megaterium ( lb in Fig. 1B). None of 
Fig. 2. Computer models of antibacterial peptides. (A), Helical models of (a) Antpe-cecropin B (AC P01509), (b) secretolytin and (c) PMAP-37. Polar 
and hydrophobic residues are indicated. (B), Computer models for secretolytin (1) together with inactive variants (peptides 3-7 in Table 1A): Residues 
which have been modified are depicted in solid representation. 
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Table 1 
Sequence omparison of the antibacterial secretolytin (CGBb) with the 
homologous cbromogranin-derived peptides (CGBh, CGBm and 
CGBr), PMAP-37, and cecropins from different species Sequence align- 
ment was performed using the Clustal V multiple sequence alignment 
program [19]. 
1 CGB-b 
2 CGB-h 
3 CGB-m 
4 CGB-r 
5 PMAP-37 
6 Cecl_Cerca 
7 Cecl_Pig 
8 Cec2_Manse 
9 Cec4_Bommo 
10 CecA_Bommo 
11 CecA_Hyace 
12 CecB_Antpe 
13 CecB_Drome 
14 CecB_Hyaee 
15 CecC_Drome 
16 CecD_Hyace 
17 SrlC_Sarpe 
18 SrlD_Sarpe 
Q K I IA 
Q K I IA  
Q K I i 
G E K I 
G K K I I 
A K K LI 
F K E L 
F K K I I 
F K K I 
F K K I 
F K K I[ 
G K K I 
F K K I 
G K R I I  
F K E L 
G K K I 
G K R I !  
Homology (%) 89 100 
m 
~Z~rGTR~C 
EKFS]  QRG 
EKFS I  QRG 
EKFS[  QRG 
E R I G IQ  K I KD 
E R V G r Q H T R D  
ENSAIK  KR 
E R A G IQ R V R D 
E KVGIQN I RD 
EKMG[RN I RD 
EKVGIQN I RD 
E KVGIRN I RN 
ER I GrQ HT  RD 
E KMGIRN I RN 
E R I G IQ H T R D 
E K V GIQ R V R D 
ERVGJQ HTR D 
E R V G IQ H T R D 
100 94 89 100 100 
Consensus K/R I/L E K/R X~ X2 R/K 
XI=F, V, I, M. 
X2=G , A, S. 
the modified peptides numbered 3-7 nor tryptic digest num- 
bered 11 had any effect on the growth of Micrococcus luteus 
suggesting the importance of: (i) the length of the peptide to 
interact with the microbial membrane, (ii) the presence of basic 
residues K2, K6 and R11 and (iii) the presence of hydrophobic 
residues I3 and F7. In addition, these data show that the anti- 
bacterial activity seems to be specific to bovine CGB (614-626). 
3.2. Antibacterial activity of secretolytin is related with the 
extracellular processing of chromogranin B Isecretogranin 
I (CGB) 
The study of the processing of CGB in bovine chromaffin 
granules allowed us to characterize the different cleavage sites 
along the protein chain [7]. Secretolytin, the major CGB-de- 
rived fragment (614-626) was identified in the extracellular 
medium from directly depolarized bovine cultured chromaffin 
cells. In secretory granules, its immediate precursor is the 610- 
626 fragment [7]. This fragment was synthesized (peptide 8 in 
Fig. IA) and found to be inactive against bacteria growth. The 
natural peptide extracted from the soluble granule core was 
also inactive. In order to compare the antibacterial ctivity of 
secretolytin with the larger CGB fragment, allowing its align- 
ment with cecropin 1-15, the corresponding peptide 9(Fig. 1A) 
was synthesized. This peptide was inactive towards the growth 
of the bacteria gram-positive Micrococcus luteus (Fig. 1B). 
Since the aromatic residue in position 2 (W) of the lytic helix 
of cecropin has been described to be important for antibacterial 
activity [22], the residue M2 was changed into W2 (peptide 10): 
no antibacterial activity was found (Fig. 1B). These results 
suggest hat any additional N-terminal residues modify the 
helical conformation of secretolytin and thus abolish the anti- 
bacterial activity. 
We conclude that only secretolytin, the natural matured pep- 
tide released from cells and recovered in the extracellular me- 
dium, and its corresponding synthetic peptide possess the 
length and the residues necessary for the antibacterial ctivity 
against bacteria gram-positive. 
3.3. Sequence comparison of secretolytin with the corresponding 
sequences of CGB from several species, cecropins and 
PMAP-37 
The alignment of secretolytin with homologous (inactive) 
CGB fragments from human (sequence 2), mouse (sequence 3) 
and rat (sequence 4) and with cecropins from different species 
(sequences 6-18) is shown in Table 1. Recently, a novel anti- 
bacterial peptide composed of 37 residues has been extracted 
and purified from myeloid tissue and named PMAP-37 (Por- 
cine Myeloid Antibacterial Peptide) [13]. In the sequence of 
PMAP-37 a central fragment (sequence 5) shows a high degree 
of similarity with the active domain of cecropin B. Sequence 
alignment confirms the consensus sequence confering the anti- 
bacterial activity: X-X-KIR-IIL-X-E-KIR-F/VIMll/-GIAIS-X- 
X-X-R/K-X (Table 1). By comparison with the consensus pat- 
tern for cecropins previously proposed : W-X(0,2)-K/N-X-X- 
K-K/E-L/I-E-R/K/N [23; PS00268], the alignment reported in 
Table 1 suggests that the C-terminal moiety is crucial to anti- 
bacterial activity. 
3.4. Structural properties of secretolytin 
From the alignment data (Table 1), a comparative prediction 
of the secondary structure of cecropin (Antpe; sequence 12) 
from Antheraea Pernyl and bovine secretolytin (sequence 1) 
was performed according to the Homologue method provided 
in Pro-Explore (Fig. 2A). Studying the antibacterial ctivity of 
6 analogues to the 37-residue cecropin A, Andreu et al. [22] 
demonstrated that the s-helical 5-21 region of cecropin A was 
clearly involved in the interaction against Micrococeus luteus, 
Bacillus megaterium and Pseudomonas aeruginosa. All modifi- 
cations causing conformational changes in this region had a 
marked effect on the activity of the corresponding peptide indi- 
cating a strong correlation between the loss of helicity and 
absence of antibacterial ctivity. As shown in Fig. 2A, the 2 
peptides cecropin-Antpe (model a) and secretolytin (model b) 
have a similar arrangement concerning polar and hydrophobic 
residues (K2, E5, K6, R12, I314 and F/V7). The charged and 
polar groups are grouped together suggesting that the basic 
amino acids could interact with the negatively charged 
phospholipids of the bacterial membranes. Both models predict 
a hydrophobic domain covering approximatively one third of 
the molecule which is likely to orientate the peptide towards the 
hydrophobic ore of membranes [24]. Furthermore, several 
possibilities of internal interactions between charged groups 
exist. The most significant of them is that the 6 carboxylate 
group of E5 is so close to the e amino group of K2 and K6 that 
a hydrogen bond or salt link may be formed, contributing to 
the stabilization of the helix. For PMAP-37 (model c ; Fig. 2A), 
the predicted model shows a similar arrangement of charged 
residues (E2, E5, R6, K12 and D13) defining a hydrophobic 
domain comprising the 3 residues I4, I7 and I11. 
Previously, we determined the circular dichroism spectra of 
the synthetic secretolytin at various pHs and in the presence or 
absence of trifluoroethanol [7]. The results howed that increas- 
ing amounts of trifluoroethanol induced a higher c~-helical con- 
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tent. In 100% trifluroethanol, the circular dichroism spectra 
became clearly helical as characterized by two negative bands 
at 208 and 220 nm. More recently, experiments were performed 
by use of a combination of two-dimensional NMR techniques 
(NOESY, two-dimensional nuclear Overhauser effect spectros- 
copy and HOHAHA, homonuclear Hartmann-Hahn spectros- 
copy). Results obtained at 25°C and 40°C show an equilibrium 
between two conformations of the sequence Q1 to G9, includ- 
ing respectively oops located at K2-I3 and A4-E5 (25°C) and 
loops located at A4-E5 and F7-$8 (40°C). In addition, aunique 
non-structured conformation was assigned for the C-terminal 
sequence T10-G 13. In these conditions, the stabilization of the 
helical structure by the interaction between E5 and K2/K6 
seems possible in peptide conformations obtained at 40°C and 
including loops A4/E5 and F7/$8. 
These results show that in aqueous olution secretolytin pre- 
sents a conformational flexibility. Two parameters are impor- 
tant to define the flexibility of this peptide. The first concerns 
the rate at which conformational changes occur, and another 
is the energetics of the various conformations. In addition, 
amino acid side chains of peptides present into membrane are 
much more restricted in their flexibility than are those of pep- 
tides in aqueous olutions. Taking into account his last point, 
it seems now important o further define the interaction of 
secretolytin with phospholipid vesicles. 
In 1989, the first mammalian cecropin was isolated from pig 
small intestine [12]. This peptide, porcine cecropin P1, presents 
extensive homology with insect cecropins except hat it is not 
amidated on the C-terminus. In addition, cecropin P1 has a 
more narrow antibacterial spectrum. The structures of cecropin 
A and a hybrid of cecropin A and mellitin in solution have been 
determined by Holak et al. [20] and Sipos et al. [25]. More 
recently, the conformation of the mammalian cecropin P1 has 
been studied by two-dimensional NOE spectroscopy (NOESY) 
[21]. The conclusion from these studies is that a central region 
of P1 composed of 13 or 14 residues forms a well identified 
or-helix. Adjacent o this region, there is another, rather well- 
characterized s-helix structure which bends away from the first 
cz-helix axis. The first 2~ residues in the N-terminus and the 
last 3-5 residues in the C-terminus are not structurally well 
determined and are likely to be flexible. 
It is important o point out that the structure of porcine 
cecropin P1 in solution is remarkably different from the struc- 
tures of insect cecropins [20], mellitin [26] or a hybrid between 
these last two [25]. Whereas porcine cecropin shows a continu- 
ous amphipathic or-helix over nearly the whole length of the 
peptide, the structure of insect cecropins consists of two helices 
connected by a flexible hinge. The N-terminal helix is amphipa- 
thic while the other internal s-helix is essentially hydrophobic. 
Using the Homologue method in Pro-Explore, secondary 
structure predictions for secretolytin (peptide 1) and for differ- 
ent related peptides (peptides 3to 7 in Fig. 1A) were compared 
(Fig. 2B). Residues K2, K6, 13 and F7 in the prediction model 
1 and residue A which replaces these residues in models 5, 6 and 
7 have been represented as compact models. These models 
show clearly the structural features critical for the antibacterial 
activity as previously discussed (see above). 
3.5. Antibacterial mechanisms 
Antibacterial peptides are produced by numerous pecies 
from different classes including mammals, amphibians and in- 
sects. These peptides appear to play an important role in the 
innate immune response to invasion by pathogenic microorgan- 
isms [27]. Nevertheless, the precise mode of action of these 
antibacterial peptides is not yet fully understood. It has been 
suggested that the antibacterial ctivity appears to be due to the 
permeation of membranes via peptide-lipid interaction, rather 
than to receptor-mediated recognition [28,29]. To understand 
the structural requirements for this antibacterial ctivity, the 
enianto, retro, and retroenianto isomers of hybrid analogs of 
cecropin were synthesized [30]. They concluded that chirality 
of peptide was not a critical feature, and full activity could be 
achieved with peptides containing either all L- or D-amino acids 
in their respective right- or left-handed helical conformations. 
Recently, studies on the interaction of pig cecropin with 
phospholipid vesicles have been reported [14]. By using a vari- 
ety of biophysical methods (e.g. fluorescence spectroscopy, 
NMR), a non-pore mechanism was suggested as a possible 
mode of action of magainins [31], dermaseptin [24] and insect 
cecropins [14]. Further support for non-pore mechanism as the 
mode of action comes from the finding that cecropin-mellitin 
hybrids as short as 15 amino acids [32], or the 12 amino acid 
N-terminal analogue of dermaseptin [33] had antibacterial c- 
tivity similar to that displayed by their intact parent molecules. 
The antibacterial characterization f secretolytin and PMAP- 
37 provides further examples arguing for the non-pore mecha- 
nism. The lengths of these a-helices are too short to span the 
30/k thick phospholipid bilayers membrane and form a con- 
ducting pore. 
Antibacterial peptides have to be positively charged in order 
to bind to bacterial surfaces, which are negatively charged. In 
the non-pore mechanism suggested for the antibacterial peptide 
dermaseptin [24], four steps were possibly required. One of the 
steps include the laying of amphipathic or-helical monomers on 
the surface of the membrane such that the positive charges of 
the basic amino acids interact with the negatively charged phos- 
pholipid headgroups or water molecules. Secretolytin presents 
a similar basic feature with a net charge of +3. The different 
unactive peptides reported on Fig. 1A have a net charge of +2 
that may be too low to allow interaction of the peptide with the 
bacterial membrane. The inability of peptide 7 (net charge of 
+3) to inhibit bacterial growth may be related to the presence 
of two residues A3 and A7 in place of the hydrophobic residues 
I3 and F7 which prevent he building of an amphipathic helix. 
3.6. Conclusions 
During the past few years, much has been learned about the 
biochemistry and cell biology of chromogranins, but the func- 
tion of these proteins and their derived peptides is still unclear. 
However, the use of these proteins as neuroendocrine tumor 
markers has been clearly defined [34] and in Alzheimer's dis- 
ease, CGA is colocalized with beta-amyloid precursor protein 
in senile plaques [35]. With the antibacterial properties dis- 
played by secretolytin we have determined a new cryptic biolog- 
ical activity associated with endogenous chromogranin-derived 
peptides. The interesting structural homology of secretolytin 
with cecropins and PMAP-37 suggests that a common o-helical 
amphipathic domain may underlie this antibacterial ctivity. 
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